FEMASYS INC (FEMY)
FEMASYS INC (FEMY)
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Sales | NaN | 2,293,313 | NaN | NaN |
| Cost of sales (excluding depreciation expense) | NaN | 872,400 | NaN | NaN |
| Research and development expense | NaN | 2,072,771 | NaN | NaN |
| Other research and development expenses | NaN | 5,504,933 | NaN | NaN |
| Total research and development expense | NaN | 7,577,704 | NaN | NaN |
| Sales and marketing expense | NaN | 4,443,807 | NaN | NaN |
| General and administrative expense | NaN | 6,646,037 | NaN | NaN |
| Depreciation and amortization expense | NaN | 342,034 | NaN | NaN |
| Total operating expenses | NaN | 19,009,582 | NaN | NaN |
| Total other expense, net | NaN | -1,037,921 | NaN | NaN |
| Loss before income taxes | NaN | -18,626,590 | NaN | NaN |
| Income tax expense | NaN | 1,297 | NaN | NaN |
| Net income (loss) | 846,100 | -3,950,305 | -4,194,821 | -10,482,761 |
| Depreciation | 65,578 | 68,488 | 72,022 | 155,349 |
| Amortization | 16,692 | 16,711 | 13,675 | 15,789 |
| Other noncash items | NaN | -5,724 | NaN | NaN |
| Change in fair value of conversion option liability | -1,513,413 | -503,000 | NaN | NaN |
| Change in fair value of warrants liabilities | -3,683,000 | -731,000 | NaN | NaN |
| Amortization of right-of-use assets | 118,180 | 122,224 | 125,379 | 260,819 |
| Loss on fixed asset dispositions | 0 | -9,477 | 0 | -53,173 |
| Share-based compensation expense | 151,608 | 66,423 | 174,514 | 549,208 |
| Amortization of debt issuance costs and discount | NaN | 213,897 | 426,541 | 746,612 |
| Accretion of paid-in-kind interest | NaN | 132,140 | NaN | NaN |
| Amortization of debt issuance costs and discount | -176,607 | NaN | NaN | NaN |
| Accounts receivable | -444,336 | 44,401 | 317,615 | -233,789 |
| Inventory | 365,018 | -43,725 | 551,236 | 2,186,415 |
| Prepaid and other assets | -168,722 | -213,520 | -118,326 | -165,056 |
| Accounts payable | -253,439 | -321,574 | -1,101,759 | 1,758,162 |
| Accrued expenses | -193,226 | 597,312 | -24,291 | -98,297 |
| Lease liabilities | -125,280 | -125,117 | -128,270 | -264,580 |
| Other liabilities | 2,045 | 516 | 160 | -23,854 |
| Net cash used in operating activities | -4,143,508 | -4,185,240 | -5,387,375 | -9,117,950 |
| Acquisition of patents | NaN | 56,875 | 45,483 | 2,733 |
| Purchases of property and equipment | 79,138 | 139,840 | 194,333 | 190,834 |
| Net cash used in investing activities | -79,138 | -196,715 | -239,816 | -193,567 |
| Proceeds from the issuance of common stock-Warrants Eight | NaN | 0 | 4,510,001 | NaN |
| Issuance costs-Warrants Eight | NaN | 0 | 804,940 | NaN |
| Proceeds from the issuance of common stock-Warrants Nine | NaN | 0 | 7,998,826 | NaN |
| Issuance costs-Warrants Nine | NaN | 0 | 930,132 | NaN |
| Proceeds from exercise of pre-funded warrants | NaN | 71 | 429 | NaN |
| Proceeds from exercise of common warrants | NaN | 3,318,879 | NaN | NaN |
| Proceeds from november 2025 convertible notes | NaN | 12,000,000 | NaN | NaN |
| Issuance costs for november 2025 convertible notes | NaN | 718,528 | NaN | NaN |
| Proceeds from common stock issued through espp | NaN | 49,457 | 0 | 40,875 |
| Proceeds from the issuance of common stock in june 2025 financing | NaN | NaN | NaN | 4,510,001 |
| Issuance costs for june 2025 financing | NaN | NaN | NaN | 804,940 |
| Proceeds from at-the-market sales of common stock | 352,922 | 1,516,371 | 0 | 5,496,791 |
| Issuance costs for at-the-market sales of common stock | 10,588 | 45,491 | 0 | 164,904 |
| Repayment of november 2023 convertible notes, including related parties | NaN | 6,765,000 | NaN | NaN |
| Repayment of note payable | NaN | 276,489 | 90,961 | NaN |
| Net cash provided by financing activities | 342,334 | 9,079,270 | 6,978,162 | 9,077,823 |
| Net change in cash and cash equivalents | -3,880,312 | 4,697,315 | 1,350,971 | -233,694 |
| Beginning of period | 9,266,353 | -1,117,277 | 3,451,761 | NaN |
| End of period | 5,386,041 | 4,697,315 | 4,569,038 | NaN |